VHL - Von Hippel-Lindau Syndrome
4 clinical trials · Condition
◉ Watch VHL - Von Hippel-Lindau Syndrome
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) (NCT03401788) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-05-02 |
Track VHL - Von Hippel-Lindau Syndrome automatically
Every clearance here is in the API, with alerts when new ones post.